Workflow
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ABCLAbCellera Biologics(ABCL) Zacks Investment Research·2024-02-21 01:01

AbCellera Biologics Inc. (ABCL) reported 9.18millioninrevenueforthequarterendedDecember2023,representingayear−over−yeardeclineof57.49.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -0.17 for the same period compares to -0.10ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of 9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.While investors scrutinize revenue and earnings changes year-over-year and how they com ...